Tomorrow, we’ll be joining approximately 20,000 cancer researchers in New Orleans for the annual American Association for Cancer Research (AACR) meeting. Vice President Joe Biden will also be there to speak about the “Cancer Moonshot” and the future of cancer research.
At this year’s meeting, we will have more than 15 genitourinary (GU) oncology clinicians and scientists from Weill Cornell Medicine presenting on a wide range of GU cancer research updates and clinical trial results.
We have a lot to share at AACR 2016, so we’ll be updating the blog almost daily throughout the week.
Be on the lookout, but here are some highlights of what’s to come:
- Insights regarding drug resistance and prostate cancer
- An update on treatment options for people with renal cell carcinoma (RCC), the most common kidney cancer in adults
- How epigenetic therapy and precision medicine may help us better treat neuroendocrine prostate cancer (NEPC)
- Clinical trial results for immunotherapies in bladder and other urothelial cancers
- Non-invasive ways to detect, diagnose and treat prostate cancers, including circulating tumor cells and molecularly-targeted nanoparticles